This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Revascularization  • Cardiovascular System  • Surgery  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Genetics  • Genetic Counseling/ Testing/ Therapy  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

Vincent R. Conti, MD; Glenn C. Hunter, MD

JAMA. 2005;294:2495-2497. Published online November 13, 2005 (doi:10.1001/jama.294.19.jed50077).

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A major and much-needed advance for cardiac surgeons and patients requiring coronary artery bypass graft (CABG) surgery would be the availability of an easily applied intervention that would improve long-term patency rates for saphenous vein grafts to those achieved with internal thoracic artery grafts. With newer endoscopic techniques, the saphenous vein can be harvested with minimal trauma and without compromising short-term patency rates.^1-2 While saphenous vein grafts are the easiest conduits to use technically, especially for sequential grafting, the internal thoracic artery, with its excellent long-term patency (especially when used to the left anterior descending vessel), will remain the preferred primary conduit in the vast majority of cases.

Saphenous vein graft failure has a trimodal distribution. Early failure occurs within the first 1 to 2 months, probably from primary thrombosis due to technical factors, poor runoff into small or severely diseased distal . . . [Full Text of this Article]

Author Affiliation: Department of Surgery, University of Texas Medical Branch, Galveston.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Efficacy and Safety of Edifoligide, an E2F Transcription Factor Decoy, for Prevention of Vein Graft Failure Following Coronary Artery Bypass Graft Surgery: PREVENT IV: A Randomized Controlled Trial
PREVENT IV Investigators
JAMA. 2005;294(19):2446-2454.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Recurrent angina after coronary revascularization: a clinical challenge
Abbate et al.
Eur Heart J 2007;28:1057-1065.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Edifoligide
Lau and Kritharides
JAMA 2006;295:1513-1514.
FULL TEXT  

An Attempt to Prevent Vein-Graft Failure After CABG
Journal Watch Cardiology 2005;2005:2-2.
FULL TEXT